Search

everythinglearnresearchcommunity

for

Search:↓

The vitamin D receptor has many roles in the body beyond managing calcium, affecting the immune system, hair growth, muscles, fat, bone marrow, and cancer cells.

Ritlecitinib is safe and may effectively treat alopecia areata.

Vitamin D receptor helps prevent skin cancer and supports skin health.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.

Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Echinops echinatus and Tridax procumbens have compounds that fight bacteria.

Confocal Raman microscopy can effectively study drug delivery in hair follicles using pig ear models.

Baricitinib can cause excessive hair growth.

TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.

Terminalia bellirica extracts effectively promote hair regrowth and treat androgenetic alopecia.

GRF is not safe for tubal occlusion.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Ayurvedic treatments improved alopecia areata symptoms.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Certain defective glucocorticoid receptor mutants move faster inside cell nuclei and work less effectively.

PRP-based treatments can increase hair density, but results vary among individuals.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.

Topical ruxolitinib quickly improves non-segmental vitiligo.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

JAK inhibitors show promise for treating various skin diseases.